Combined administration of EGCG and IL-1 receptor antagonist efficiently downregulates IL-1-induced tumorigenic factors in U-2 OS human osteosarcoma cells

International Journal of Oncology

Volumn 41, Issue 2, 2012, Pages 753-758

  Hönicke, Anne Sophie ^a   Ender, Stephan Albrecht ^a   Radons, Jürgen ^a,b  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b Multimmune GmbH   (Germany)

Author keywords

( ) Epigallocatechin 3 gallate; IL 1 receptor antagonist; Interleukin 1; Osteosarcoma; U 2 OS

Indexed keywords

CASPASE 3; EPIGALLOCATECHIN GALLATE; GELATINASE A; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN MDM2; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOGENIC ACTIVITY; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; METABOLISM; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEA; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

ANTINEOPLASTIC AGENTS; CASPASE 3; CATECHIN; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-6; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 2; OSTEOSARCOMA; RECEPTORS, INTERLEUKIN-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863582759     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1498     Document Type: Article

References (51)

1. Longhi A, Pasini A, Cicognani A, et al: Height as a risk factor for osteosarcoma. J Pediatr Hematol Oncol 27: 314-318, 2005. (Pubitemid 40885161)
2. Vigorita VJ and Ghelman B (eds): Orthopaedic Pathology. 2nd edition. Lippincott, Williams and Wilkins, Philadelphia, PA, 2008.
3. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790, 2002. (Pubitemid 34111386)
4. Hegyi M, Semsei AF, Jakab Z, et al: Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy. Pediatr Blood Cancer 57: 415-422, 2011.
5. Khan N, Afaq F and Mukhtar H: Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 10: 475-510, 2008.
6. Shankar S, Ganapathy S, Hingorani SR and Srivastava RK: EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 13: 440-452, 2008. (Pubitemid 351599756)
7. Yang CS, Lambert JD, Ju J, Lu G and Sang S: Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol Appl Pharmacol 224: 265-273, 2007. (Pubitemid 47592860)
8. Khan N and Mukhtar H: Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett 269: 269-280, 2008.
9. Hussain SP and Harris CC: Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121: 2373-2380, 2007. (Pubitemid 350022405)
10. Multhoff G, Molls M and Radons J: Chronic inflammation in cancer development. Front Immunol 2: 98, 2012.
11. Terpos E and Dimopoulos MA: Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications. Cancer Immunol Immunother 60: 305-317, 2011.
12. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454: 436-444, 2008.
13. Smida J, Baumhoer D, Rosemann M, et al: Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res 16: 4256-4267, 2010.
14. Ta HT, Dass CR, Choong PF and Dunstan DE: Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 28: 247-263, 2009.
15. Heinsohn S, Evermann U, Zur SU, Bielack S and Kabisch H: Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma. Int J Oncol 30: 1205-1214, 2007.
16. Longhi A, Benassi MS, Molendini L, Macchiagodena M, Picci P and Bacci G: Osteosarcoma in blood relatives. Oncol Rep 8: 131-136, 2001. (Pubitemid 33758215)
17. Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183, 2007.
18. Voronov E, Carmi Y and Apte RN: Role of IL-1-mediated inflammation in tumor angiogenesis. Adv Exp Med Biol 601: 265-270, 2007.
19. Baamonde A, Curto-Reyes V, Juarez L, Meana A, Hidalgo A and Menendez L: Antihyperalgesic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1beta levels in inflamed and osteosarcoma-bearing mice. Life Sci 81: 673-682, 2007. (Pubitemid 47268018)
20. Lewis AM, Varghese S, Xu H and Alexander HR: Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 4: 48, 2006.
21. Apte RN, Krelin Y, Song X, et al: Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer 42: 751-759, 2006.
22. Rutkowski P, Kaminska J, Kowalska M, Ruka W and Steffen J: Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 84: 151-159, 2003. (Pubitemid 37363158)
23. Gay NJ, Gangloff M and O'Neill LA: What the Myddosome structure tells us about the initiation of innate immunity. Trends Immunol 32: 104-109, 2011.
24. Watters TM, Kenny EF and O'Neill LA: Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol 85: 411-419, 2007. (Pubitemid 47367505)
25. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006.
26. Singh S and Khar A: Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 6: 259-270, 2006. (Pubitemid 43796643)
27. Ponten J and Saksela E: Two established in vitro cell lines from human mesenchymal tumours. Int J Cancer 2: 434-447, 1967.
28. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
29. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
30. Qu Y, Xu J, Jiang T, et al: Difference in pre- and postchemotherapy vascular endothelial growth factor levels as a prognostic indicator in osteosarcoma. J Int Med Res 39: 1474-1482, 2011.
31. Korpi JT, Hagstrom J, Lehtonen N, et al: Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma. Surg Oncol 20: e18-e22, 2011.
32. Xie TX, Wei D, Liu M, et al: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23: 3550-3560, 2004. (Pubitemid 38658421)
33. Landers JE, Cassel SL and George DL: Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 57: 3562-3568, 1997. (Pubitemid 27355508)
34. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG and Healey JH: MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53: 16-18, 1993. (Pubitemid 23019370)
35. Hoffmann J, Junker H, Schmieder A, et al: EGCG downregulates IL-1RI expression and suppresses IL-1-induced tumorigenic factors in human pancreatic adenocarcinoma cells. Biochem Pharmacol 82: 1153-1162, 2011.
36. Lambert JD and Yang CS: Mechanisms of cancer prevention by tea constituents. J Nutr 133: S3262-S3267, 2003.
37. Lin JK, Liang YC and Lin-Shiau SY: Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem Pharmacol 58: 911-915, 1999.
38. Pisters KM, Newman RA, Coldman B, et al: Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 19: 1830-1838, 2001. (Pubitemid 32230886)
39. Van Amelsvoort JM, Van Hof KH, Mathot JN, Mulder TP, Wiersma A and Tijburg LB: Plasma concentrations of individual tea catechins after a single oral dose in humans. Xenobiotica 31: 891-901, 2001. (Pubitemid 34074791)
40. Chow HH, Hakim IA, Vining DR, et al: Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 11: 4627-4633, 2005. (Pubitemid 40825654)
41. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147, 1996.
42. Hedrich CM, Bruck N, Fiebig B and Gahr M: Anakinra: A safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatol Int: Nov 15, 2011 (Epub ahead of print).
43. El-Osta H, Janku F and Kurzrock R: Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther 9: 1485-1488, 2010.
44. Lust JA, Lacy MQ, Zeldenrust SR, et al: Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 84: 114-122, 2009.
45. Hoffman HM, Throne ML, Amar NJ, et al: Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58: 2443-2452, 2008.
46. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al: Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360: 2416-2425, 2009.
47. Dinarello CA: Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 29: 317-329, 2010.
48. Meyers PA: Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 9: 1035-1049, 2009.
49. Mifamurtide: osteosarcoma: ineffective and harmful. Prescrire Int 20: 89, 2011.
50. Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS and Jaffe N: Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol 10: 1310-1316, 1992.
51. Ando K, Mori K, Corradini N, Redini F and Heymann D: Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother 12: 285-292, 2011.